Affiliation:
1. The University of Sydney School of Pharmacy
2. Asbestos Diseases Research Institute
3. The University of Sydney Charles Perkins Centre
4. Centenary Institute
5. Nanjing University of Chinese Medicine
6. University of Technology Sydney
7. Inha University
8. The University of Sydney
Abstract
Abstract
Background
Respiratory diseases are the 2nd leading cause of death globally. The current treatments for chronic lung diseases are only supportive. Very few new classes of therapeutics have been introduced for lung diseases in the last 40 years, due to the lack of reliable lung models that enable rapid, cost-effective, and high-throughput testing. To accelerate the development of new therapeutics for lung diseases, we established two classes of lung-mimicking models: (i) healthy, and (ii) diseased lungs – COPD.
Methods
To establish models that mimic the lung complexity to different extents, we used five design components: (i) cell type, (ii) membrane structure/constitution, (iii) environmental conditions, (iv) cellular arrangement, (v) substrate, matrix structure and composition. To determine whether the lung models are reproducible and reliable, we developed a quality control (QC) strategy, which integrated the real-time and end-point quantitative and qualitative measurements of cellular barrier function, permeability, tight junctions, tissue structure, tissue composition, and cytokine secretion.
Results
The healthy model is characterised by (i) continuous tight junctions, (ii) physiological cellular barrier function, (iii) a full thickness epithelium composed of multiple cell layers, and (iv) the presence of ciliated cells and goblet cells. Meanwhile, the disease model emulates human COPD disease: (i) dysfunctional cellular barrier function, (ii) depletion of ciliated cells, and (ii) overproduction of goblet cells. The models developed here have multiple competitive advantages when compared with existing in vitrolung models: (i) the macroscale enables multimodal and correlative characterisation of the same model system, (ii) the use of cells derived from patients that enables the creation of individual models for each patient for personalised medicine, (iii) the use of an extracellular matrix proteins interface, which promotes physiological cell adhesion and differentiation, (iv) media microcirculation that mimics the dynamic conditions in human lungs.
Conclusion
Our model can be utilised to test safety, efficacy, and superiority of new therapeutics as well as to test toxicity and injury induced by inhaled pollution or pathogens. It is envisaged that these models can also be used to test the protective function of new therapeutics for high-risk patients or workers exposed to occupational hazards.
Publisher
Research Square Platform LLC
Reference45 articles.
1. Obstructive lung diseases burden and COVID-19 in developing countries: a perspective;Aggarwal AN;Curr Opin Pulm Med,2022
2. Extracellular Vesicles in Heart Disease: Excitement for the Future ?;Danielson KM;Exosomes and microvesicles,2014
3. attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;Prevalence;Lancet Respiratory Medicine,2020
4. Polverino F, Kheradmand F. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects.Frontiers in Medicine, 2021.7.
5. The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD);Green CE;Respir Res,2017